nach oben

DGNeurologie

Erschienen in:

12.10.2020 | Apoplex | Leitlinie Zur Zeit gratis

S1-Leitlinie: Neurologische Manifestationen bei COVID-19

Leitlinie der Deutschen Gesellschaft für Neurologie

verfasst von: Prof. Dr. med. Peter Berlit

Erschienen in: DGNeurologie | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Auszug

Die Infektion mit dem neuen „severe acute respiratory syndrome coronavirus 2“ (SARS-CoV-2) führt zu einem bisher unbekannten Krankheitsbild, welches als COVID-19 („COrona VIrus Disease 2019“) bezeichnet wird und erstmalig in der Region Hubei in China beschrieben wurde. Die Infektion wurde durch die WHO am 11.03.2020 zur Pandemie erklärt. SARS-CoV‑2 gehört zu den respiratorischen Viren („community acquired respiratory viruses“: CARV), die obere und untere Atemwegsinfektionen auslösen können. Der Erreger zählt zur Gruppe der Coronaviren, die Erkrankungen von einer normalen Erkältung bis zu schweren Krankheitsverläufen verursachen können. Verwandt mit dem SARS-CoV-2-Virus sind die Viren, die das Krankheitsbild des SARS (schweres akutes respiratorisches Syndrom) und des MERS („middle east respiratory syndrome“) verursachen und für die eine Neurotropie nachgewiesen wurde. …

Chaumont H, Etienne P, Roze E, Couratier C, Roger PM, Lannuzel A (2020) Acute meningoencephalitis in a patient with COVID-19. Rev Neurol 176(6):519–521PubMed

Ghannam M, Alshaer Q, Al-Chalabi M, Zakarna L, Robertson J, Manousakis G (2020) Neurological involvement of coronavirus disease 2019: a systematic review. J Neurol. https://doi.org/10.1007/s00415-020-09990-2CrossRefPubMedPubMedCentral

Pilotto A, Odolini S, Masciocchi S, Comelli A, Volonghi I, Gazzina S et al (2020) Steroid-responsive encephalitis in Coronavirus disease 2019. Ann Neurol. https://doi.org/10.1002/ana.25783CrossRefPubMedPubMedCentral

Duong L, Xu P, Liu A (2020) Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles, early April 2020. Brain Behav Immun 87:33PubMedPubMedCentral

Dogan L, Kaya D, Sarikaya T, Zengin R, Dincer A, Akinci IO et al (2020) Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: Case series. Brain Behav Immun 87:155–158PubMedPubMedCentral

Li YC, Bai WZ, Hashikawa T (2020) The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 92(6):552–555PubMed

Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P, Viganò M, Giovannelli G, Pirro F, Montisano DA, Appollonio I, Ferrarese C (2020) Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm 7(4):e741. https://doi.org/10.1212/NXI.0000000000000741CrossRefPubMedPubMedCentral

Arnaud S, Budowski C, Ng Wing Tin S, Degos B (2020) Post SARS-CoV‑2 Guillain-Barre syndrome. Clin Neurophysiol 131(7):1652–1654PubMedPubMedCentral

Camdessanche JP, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E (2020) COVID-19 may induce Guillain-Barre syndrome. Rev Neurol 176(6):516–518PubMed

10.

El Otmani H, El Moutawakil B, Rafai MA, El Benna N, El Kettani C, Soussi M et al (2020) Covid-19 and Guillain-Barre syndrome: more than a coincidence! Rev Neurol 176(6):518–519PubMed

11.

Gutierrez-Ortiz C, Mendez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Manas R et al (2020) Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology 95(5):e601–e605PubMed

12.

Novi G, Rossi T, Pedemonte E, Saitta L, Rolla C, Roccatagliata L, Inglese M, Farinini D (2020) Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm 7(5):e797. https://doi.org/10.1212/NXI.0000000000000797CrossRefPubMedPubMedCentral

13.

Padroni M, Mastrangelo V, Asioli GM, Pavolucci L, Abu-Rumeileh S, Piscaglia MG et al (2020) Guillain-Barre syndrome following COVID-19: new infection, old complication? J Neurol 267(7):1877–1879PubMedPubMedCentral

14.

Pfefferkorn T, Dabitz R, von Wernitz-Keibel T, Aufenanger J, Nowak-Machen M, Janssen H (2020) Acute polyradiculoneuritis with locked-in syndrome in a patient with Covid-19. J Neurol 267(7):1883–1884PubMed

15.

Scheidl E, Canseco DD, Hadji-Naumov A, Bereznai B (2020) Guillain-Barre syndrome during SARS-CoV‑2 pandemic: a case report and review of recent literature. J Peripher Nerv Syst 25(2):204–207PubMed

16.

Sedaghat Z, Karimi N (2020) Guillain Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci 76:233–235PubMedPubMedCentral

17.

Su XW, Palka SV, Rao RR, Chen FS, Brackney CR, Cambi F (2020) SARS-CoV-2-associated Guillain-Barre syndrome with dysautonomia. Muscle Nerve 62(2):E48–E49PubMed

18.

Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG et al (2020) Guillain-Barre Syndrome Associated with SARS-CoV‑2. N Engl J Med 382(26):2574–2576PubMed

19.

Zhao H, Shen D, Zhou H, Liu J, Chen S (2020) Guillain-Barre syndrome associated with SARS-CoV‑2 infection: causality or coincidence? Lancet Neurol 19(5):383–384PubMedPubMedCentral

20.

Pfeuffer S, Pawlowski M, Joos G, Minnerup J, Meuth SG, Dziewas R, Wiendl H (2020) Autoimmunity complicating SARS-CoV‑2 infection in selective IgA-deficiency. Neurol Neuroimmunol Neuroinflamm 7(6):e881. https://doi.org/10.1212/NXI.0000000000000881CrossRefPubMedPubMedCentral

21.

Parsons T, Banks S, Bae C, Gelber J, Alahmadi H, Tichauer M (2020) COVID-19-associated acute disseminated encephalomyelitis (ADEM). J Neurol 267(10):2799–2802. https://doi.org/10.1007/s00415-020-09951-9CrossRefPubMedPubMedCentral

22.

Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF (2020) Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol 140(1):1–6PubMedPubMedCentral

23.

Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B (2020) COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology. https://doi.org/10.1148/radiol.2020201187CrossRefPubMed

24.

Barzegar M, Mirmosayyeb O, Nehzat N, Sarrafi R, Khorvash F, Maghzi AH, Shaygannejad V (2020) COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol Neuroimmunol Neuroinflamm 7(4):e753. https://doi.org/10.1212/NXI.0000000000000753CrossRefPubMedPubMedCentral

25.

Borriello G, Ianniello A (2020) COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach. Mult Scler Relat Disord 41:102165PubMedPubMedCentral

26.

Foerch C, Friedauer L, Bauer B, Wolf T, Adam EH (2020) Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Mult Scler Relat Disord 42:102180PubMedPubMedCentral

27.

Ghajarzadeh M, Mirmosayyeb O, Barzegar M, Nehzat N, Vaheb S, Shaygannejad V et al (2020) Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic. Mult Scler Relat Disord 43:102222PubMedPubMedCentral

28.

Maghzi AH, Houtchens MK, Preziosa P, Ionete C, Beretich BD, Stankiewicz JM, Tauhid S, Cabot A, Berriosmorales I, Schwartz T, Sloane JA, Freedman MS, Filippi M, Weiner HL, Bakshi R (2020) COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol 267(10):2790–2796. https://doi.org/10.1007/s00415-020-09944-8CrossRefPubMedPubMedCentral

29.

Suwanwongse K, Shabarek N (2020) Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab. Mult Scler Relat Disord 42:102201PubMedPubMedCentral

30.

Sormani MP, Italian Study Group on C‑iims (2020) An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol 19(6):481–482PubMedPubMedCentral

31.

Ciampi E, Uribe-San-Martin R, Carcamo C (2020) COVID-19 pandemic: the experience of a multiple sclerosis centre in Chile. Mult Scler Relat Disord 42:102204PubMedPubMedCentral

32.

Fan M, Qiu W, Bu B, Xu Y, Yang H, Huang D, Lau AY, Guo J, Zhang MN, Zhang X, Yang CS, Chen J, Zheng P, Liu Q, Zhang C, Shi FD (2020) Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 7(5):e787. https://doi.org/10.1212/NXI.0000000000000787CrossRefPubMedPubMedCentral

33.

Pawlitzki M, Zettl UK, Ruck T, Rolfes L, Hartung HP, Meuth SG (2020) Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. EBioMedicine 56:102822PubMedPubMedCentral

34.

Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S (2020) Neuropathogenesis and neurologic manifestations of the Coronaviruses in the age of Coronavirus disease 2019: a review. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2020.2065CrossRefPubMedPubMedCentral

35.

Zheng Y, Xu H, Yang M et al (2020) Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. J Clin Virol 127:104366PubMedPubMedCentral

36.

Zhou P, Yang XL, Wang XG et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273PubMedPubMedCentral

37.

Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062PubMedPubMedCentral

38.

Chen T, Wu D, Chen H et al (2020) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368:m1091PubMedPubMedCentral

39.

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B (2020) Neurologic manifestations of hospitalized patients with Coronavirus disease 2019 in Wuhan, China. JAMA Neurol 77(6):1–9. https://doi.org/10.1001/jamaneurol.2020.1127CrossRefPubMedCentral

40.

Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M, Anheim M, Meziani F (2020). Neurologic Features in Severe SARS-CoV-2 Infection. New Engl J Med 382(23):2268–2270. https://doi.org/10.1056/NEJMc2008597CrossRefPubMed

41.

Helmsworth JA, Stiles WJ, Elstun W (1955) Leukopenic and thrombocytopenic effect of hypothermia in dogs. Proc Soc Exp Biol Med 90(2):474–476PubMed

42.

Radmanesh A, Derman A, Lui YW, Raz E, Loh JP, Hagiwara M, Borja MJ, Zan E, Fatterpekar GM (2020) COVID-19-associated Diffuse Leukoencephalopathy and Microhemorrhages. Radiology 297(1):E223–E227. https://doi.org/10.1148/radiol.2020202040CrossRefPubMed

43.

Filatov A, Sharma P, Hindi F, Espinosa PS (2020) Neurological complications of Coronavirus disease (COVID-19): encephalopathy. Cureus 12(3):e7352PubMedPubMedCentral

44.

Neumann B, Schmidbauer ML, Dimitriadis K, Otto S, Knier B, Niesen WD, Hosp JA, Günther A, Lindemann S, Nagy G, Steinberg T, Linker RA, Hemmer B, Bösel J, Pandemic and the IGNITE study groups (2020) Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms. J Neurolog Sc 418:117090. https://doi.org/10.1016/j.jns.2020.117090CrossRef

45.

Desforges M, Le Coupanec A, Brison E, Meessen-Pinard M, Talbot PJ (2014) Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans. Adv Exp Med Biol 807:75–96. https://doi.org/10.1007/978-81-322-1777-0_6CrossRefPubMedPubMedCentral

46.

Baig AM, Khaleeq A, Ali U, Syeda H (2020) Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 11(7):995–998PubMed

47.

Sepehrinezhad A, Shahbazi A, Negah SS (2020) COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review. J Neurovirol 26(3):324–329. https://doi.org/10.1007/s13365-020-00851-2CrossRefPubMedPubMedCentral

48.

Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS (2020) Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms. Internat Forum Allergy Rhinol 10(7):806–813. https://doi.org/10.1002/alr.22579CrossRef

49.

Moriguchi T, Harii N, Goto J et al (2020) A first case of meningitis/encephalitis associated with SARS-Coronavirus‑2. Int J Infect Dis 94:55–58PubMedPubMedCentral

50.

Huang YH, Jiang D, Huang JT (2020) SARS-CoV-2 Detected in Cerebrospinal Fluid by PCR in a Case of COVID-19 Encephalitis. Brain Behav Immun 87:149. https://doi.org/10.1016/j.bbi.2020.05.012CrossRefPubMedPubMedCentral

51.

Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, Sordillo EM, Fowkes M (2020) Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol 92(7):699–702. https://doi.org/10.1002/jmv.25915CrossRefPubMed

52.

Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, Braun F, Lu S, Pfefferle S, Schröder AS, Edler C, Gross O, Glatzel M, Wichmann D, Wiech T, Kluge S, Huber TB (2020) Multiorgan and Renal Tropism of SARS-CoV-2. New England J Med 383(6):590–592. https://doi.org/10.1056/NEJMc2011400CrossRef

53.

Politi LS, Salsano E, Grimaldi M (2020) Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia. Jama Neurol. https://doi.org/10.1001/jamaneurol.2020.2125CrossRefPubMed

54.

Bernard-Valnet R, Pizzarotti B, Anichini A, Demars Y, Russo E, Schmidhauser M, Cerutti-Sola J, Rossetti AO, Du Pasquier R (2020) Two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection. Europ J Neurol. https://doi.org/10.1111/ene.14298CrossRef

55.

Pilotto A, Odolini S, Masciocchi S, Comelli A, Volonghi I, Gazzina S, Nocivelli S, Pezzini A, Focà E, Caruso A, Leonardi M, Pasolini MP, Gasparotti R, Castelli F, Ashton NJ, Blennow K, Zetterberg H, Padovani A (2020) Steroid-Responsive Encephalitis in Coronavirus Disease 2019. Annals Neurol. https://doi.org/10.1002/ana.25783CrossRef

56.

Dogan L, Kaya D, Sarikaya T, Zengin R, Dincer A, Akinci IO, Afsar N (2020) Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: Case series. Brain Behavior Immunity 87:155–158. https://doi.org/10.1016/j.bbi.2020.05.022CrossRef

57.

Klok FA, Kruip MJHA, van der Meer NJM et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. https://doi.org/10.1016/j.thromres.2020.04.013CrossRefPubMedPubMedCentral

58.

Li Y, Li M, Wang M, Zhou Y, Chang J, Xian Y, Wang D, Mao L, Jin H, Hu B (2020) Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vascul Neurol 5(3):279–284. https://doi.org/10.1136/svn-2020-000431CrossRef

59.

Zhang Y, Xiao M, Zhang S et al (2020) Coagulopathy and Antiphospholipid antibodies in patients with COVID-19. N Engl J Med 382:e38PubMed

60.

Merkler AE, Parikh NS, Mir S, Gupta A, Kamel H, Lin E, Lantos J, Schenck EJ, Goyal P, Bruce SS, Kahan J, Lansdale KN, LeMoss NM, Murthy SB, Stieg PE, Fink ME, Iadecola C, Segal AZ, Campion TR Jr, Diaz I, Navi BB (2020) Risk of Ischemic Stroke in Patients with Covid-19 versus Patients with Influenza. medRxiv: the preprint server for health sciences. https://doi.org/10.1101/2020.05.18.20105494CrossRef

61.

Yamakawa M, Kuno T, Mikami T, Takagi H, Gronseth G (2020) Clinical Characteristics of Stroke with COVID-19: A Systematic Review and Meta-Analysis. J Stroke Cerebrovascular diseases 29(12):105288. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105288CrossRef

62.

Yhagi S, Ishida K, Torres J et al (2020) SARS2-coV‑2 and stroke in a New York healthcare system. Stroke. https://doi.org/10.1161/STROKEAHA.120.030335CrossRef

63.

Oxley TJ, Mocco J, Majidi S et al (2020) Clinical characteristics of five young patients presenting with large-vessel stroke. N Eng J Med. https://doi.org/10.1056/NEJMc2009787CrossRef

64.

Aggarwal G, Lippi G, Henry MB (2020) Cerebrovascular disease is associated with an increased disease severity in patients with coronavirus disease 2019 (COVID-19): a pooled analysis of published literature. Int J Stroke. https://doi.org/10.1177/174749302092166418CrossRefPubMed

65.

Pop R, Quenardelle V, Hasiu A, Mihoc D, Sellal F, Dugay MH (2020) Impact of the COVID-19 outbreak on acute stroke pathways—insights from the Alsace region in France. Eur J Neurol. https://doi.org/10.1111/ene.14316CrossRefPubMedPubMedCentral

66.

Baracchini C, Pieroni A, Viaro F et al (2020) Acute stroke management pathway during Coronavirus-19 pandemic. Neurol Sci 41:1003–1005. https://doi.org/10.1007/s10072-020-04375-9CrossRefPubMed

67.

Zhao J, Li H, Kung D, Fisher M, Shen Y, Liu R (2020) Impact of the COVID-19 epidemic on stroke care and potential solutions. Stroke. https://doi.org/10.1161/STROKEAHA.120.030225CrossRefPubMedPubMedCentral

68.

Leira EC, Russmann AN, Biller J et al (2020) Preserving stroke care during the COVID-19 pandemic. Potential issues and solutions. Neurology. https://doi.org/10.1212/WNL.0000000000009713CrossRefPubMedPubMedCentral

69.

Yang B, Wang T, Chen J et al (2020) Impact of the COVID-19 pandemic on the process and outcome of thrombectomy for acute ischemic stroke. J Neurointerv Surg 12(7):664–668PubMed

70.

Khosravani H, Rajendram P, Notario L, Chapman MG, Menon BK (2020) Protected Code Stroke: Hyperacute Stroke Management During the Coronavirus Disease 2019 (COVID-19) Pandemic. Stroke 51(6):1891–1895. https://doi.org/10.1161/STROKEAHA.120.029838CrossRefPubMed

71.

Sharma D, Rasmussen M, Han R et al (2020) Anesthetic Management of Endovascular Treatment of Acute Ischemic Stroke During COVID-19 Pandemic: Consensus Statement From Society for Neuroscience in Anesthesiology & Critical Care (SNACC): Endorsed by Society of Vascular & Interventional Neurology (SVIN), Society of NeuroInterventional Surgery (SNIS), Neurocritical Care Society (NCS), European Society of Minimally Invasive Neurological Therapy (ESMINT) and American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) Cerebrovascular Section. J Neurosurg Anesthesiol 32(3):193–201PubMed

72.

Qureshi AI, Abd-Allah F, Al-Senani F, Aytac E, Borhani-Haghighi A, Ciccone A, Gomez CR, Gurkas E, Hsu CY, Jani V, Jiao L, Kobayashi A, Lee J, Liaqat J, Mazighi M, Parthasarathy R, Miran MS, Steiner T, Toyoda K, Ribo M, Wang Y (2020) Management of acute ischemic stroke in patients with COVID-19 infection: Insights from an international panel. Amer J Emerg Med 38(7):1548.e5–1548.e7. https://doi.org/10.1016/j.ajem.2020.05.018

73.

Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, Tomson T, Hauser WA (2010) Recommendation for a definition of acute symptomatic seizure. Epilepsia 51(4):671–675PubMed

74.

DGN-Kommission Epilepsien und Synkopen. Stellungnahme der Kommission zu Covid-19 Infektionen und Epilepsie. www.dgn.org/rubrik-dgn/3771-2-19-epilepsien-und-synkopen

75.

French JA, Brodie MA, Caraballo R, Devinsky O, Ding D, Jehi L, Jette N, Kanner A, Modi AC, Newton CR, Patel AA, Pennell PB, Perucca E, Sander JW, Scheffer IE, Williams E, Wilmshorst J, Cross JH (2020) Keeping people with epilepsy safe during the Covid pandemic. Neurology 94(23):1032–1037. https://doi.org/10.1212/WNL.0000000000009632CrossRefPubMedPubMedCentral

76.

Karimi N, Shafiri Razavi A, Rouhani N (2020) Frequent convulsive seizures in an adult patient with COVID-19: a case report. Iran Red Crescent Med J 22(3):e102828

77.

Lu L, Xiong W, Liu D, Liu J, Yang D, Li N, Mu J, Guo J, Li W, Wang G, Gao H, Zhang Y, Lin M, Chen L, Shen S, Zhang H, Sander JW, Luo J, Chen S, Zhou D (2020) New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study. Epilepsia 61(6):e49–e53. https://doi.org/10.1111/epi.16524CrossRefPubMed

78.

Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L et al (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. https://doi.org/10.1016/j.bbi.2020.03.031CrossRefPubMedPubMedCentral

79.

Vollono C, Rollo E, Romozzi M, Frisullo G, Servidei S, Borghetti A, Calabresi P (2020) Focal status epilepticus as unique clinical feature of COVID-19: a case report. Seizure 78:109–112. https://doi.org/10.1016/j.seizure.2020.04.009CrossRefPubMedPubMedCentral

80.

Lai SL, Hsu MT, Chen SS (2005) The impact of SARS on epilepsy: the experience of drug withdrawal in epileptic patients. Seizure 14(8):557–561PubMedPubMedCentral

81.

Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, Ueno M, Sakata H, Kondo K, Myose N, Nakao A, Takeda M, Haro H, Inoue O, Suzuki-Inoue K, Kubokawa K, Ogihara S, Sasaki T, Kinouchi H, Kojin H, Ito M, Onishi H, Shimizu T, Sasaki Y, Enomoto N, Ishihara H, Furuya S, Yamamoto T, Shimada S (2020) A first case of meningitis/encephalitis associated with SARS-Coronavirus‑2. Int J Infect Dis 94:55–58PubMedPubMedCentral

82.

Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM, Damm M, Frasnelli J, Gudziol H, Gupta N, Haehner A, Holbrook E, Hong SC, Hornung D, Hüttenbrink KB, Kamel R, Kobayashi M, Konstantinidis I, Landis BN, Leopold DA, Macchi A, Miwa T, Moesges R, Mullol J, Mueller CA, Ottaviano G, Passali GC, Philpott C, Pinto JM, Ramakrishnan VJ, Rombaux P, Roth Y, Schlosser RA, Shu B, Soler G, Stjärne P, Stuck BA, Vodicka J, Welge-Luessen A (2017) Position paper on olfactory dysfunction. Rhinol Suppl 25:1–30

83.

Stevenson RJ (2010) An initial evaluation of the functions of human olfaction. Chem Senses 35(1):3–20. https://doi.org/10.1093/chemse/bjp083CrossRefPubMed

84.

Buck L, Axel R (1991) A novel multigene family may encode odorant receptors: a molecular basis for odor recognition. Cell 65(1):175–187. https://doi.org/10.1016/0092-8674(91)90418-xCrossRefPubMed

85.

Shepherd GM (2007) Perspectives on olfactory processing, conscious perception, and orbitofrontal cortex. Ann N Y Acad Sci 1121:87–101. https://doi.org/10.1196/annals.1401.032CrossRefPubMed

86.

DeMaria S, Ngai J (2010) The cell biology of smell. J Cell Biol 191(3):443–452. https://doi.org/10.1083/jcb.201008163CrossRefPubMedPubMedCentral

87.

Bednár M (1930) Anosmie und Influenza (Ein rhinologischer Beitrag zur Differentialdiagnose der Erkältungskrankheiten). Med Klin 48:1787–1789

88.

Konstantinidis I, Haehner A, Frasnelli J, Reden J, Quante G, Damm M, Hummel T (2006) Post-infectious olfactory dysfunction exhibits a seasonal pattern. Rhinology 44:135–139PubMed

89.

Schaupp H (1972) Geruchsstörungen nach Grippe. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 199:692–698

90.

Sugiura M, Aiba T, Mori J, Nakai Y (1998) An epidemiological study of postviral olfactory disorder. Acta Otolaryngol Suppl 538:191–196PubMed

91.

Arbour N, Day R, Newcombe J, Talbot PJ (2000) Neuroinvasion by human respiratory coronaviruses. J Virol 74(19):8913–8921. https://doi.org/10.1128/jvi.74.19.8913-8921.2000CrossRefPubMedPubMedCentral

92.

Wu Y, Xu X, Chen Z et al (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 87:18–22. https://doi.org/10.1016/j.bbi.2020.03.031CrossRefPubMedPubMedCentral

93.

Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450–454PubMedPubMedCentral

94.

Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S (2008) Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol 82(15):7264–7275. https://doi.org/10.1128/JVI.00737-08CrossRefPubMedPubMedCentral

95.

Hwang CS (2006) Olfactory neuropathy in severe acute respiratory syndrome: report of a case. Acta Neurol Taiwan 15(1):26–28PubMed

96.

Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, Talavera-López C, Maatz H, Reichart D, Sampaziotis F et al (2020) 2020. SARS-cov‑2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 26(5):681–687. https://doi.org/10.1038/s41591-020-0868-6CrossRefPubMedPubMedCentral

97.

Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-coV‑2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052CrossRefPubMedPubMedCentral

98.

Kirschenbaum D, Imbach LL, Ulrich S, Rushing EJ, Keller E, Reimann RR, Frauenknecht K, Lichtblau M, Witt M, Hummel T, Steiger P, Aguzzi A, Frontzek K (2020) Inflammatory olfactory neuropathy in two patients with COVID-19. Lancet 396(10245):166. https://doi.org/10.1016/S0140-6736(20)31525-7CrossRef

99.

van Riel D, Verdijk R, Kuiken T (2015) The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system. J Pathol 235:277–287. https://doi.org/10.1002/path.4461CrossRefPubMed

100.

Puelles VG, Lütgehetmann M, Lindenmeyer MT et al (2020) Multiorgan and renal tropism of SARS-coV‑2. N Eng J Med. https://doi.org/10.1056/NEJMc2011400CrossRef

101.

Zhu N, Zhang D, Wang W et al (2020) A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 382:727–733PubMedPubMedCentral

102.

Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. https://doi.org/10.1056/NEJMoa2002032CrossRefPubMedPubMedCentral

103.

Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506PubMedPubMedCentral

104.

Grasselli G, Zangrillo A, Zanella A et al (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-coV‑2 admitted to ICus of the Lombardy region, Italy. JAMA. https://doi.org/10.1001/jama.2020.5394CrossRefPubMedPubMedCentral

105.

Dreher MKA, Kersten A, Bickenbach J et al (2020) Charakteristik von 50 hospitalisierten COVID-19-Patienten mit und ohne ARDS. Dtsch Arztebl Int 117:271–278. https://doi.org/10.3238/arztebl.2020.0271CrossRefPubMedPubMedCentral

106.

Bagheri SH, Asghari A, Farhadi M, Shamshiri AR, Kabir A, Kamrava SK, Jalessi M, Mohebbi A, Alizadeh R, Honarmand AA, Ghalehbaghi B, Salimi A, Dehghani Firouzabadi F (2020) Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak in Iran. Med J Islamic Rep Iran 34:62. https://doi.org/10.34171/mjiri.34.62CrossRef

107.

https://dgn.org/wp-content/uploads/2020/08/030144_Tabellen_Stoerungen_der_Chemosensorik-1.pdf

108.

Hintschich CA, Wenzel JJ, Hummel T et al (2020) Psychophysical tests reveal impaired olfaction but preserved gustation in COVID-19 patients. Int Forum Allergy Rhinol. https://doi.org/10.1002/alr.22655CrossRefPubMedPubMedCentral

109.

Haehner A, Draf J, Dräger S, de With K, Hummel T (2020) Predictive value of sudden olfactory loss in the diagnosis of COVID-19. Orl J Otorhinolaryngol Relat Spec. https://doi.org/10.1159/000509143CrossRefPubMed

110.

Whitcroft KL, Hummel T (2019) Clinical diagnosis and current management strategies for olfactory dysfunction: a review. JAMA Otolaryngol Head Neck Surg. https://doi.org/10.1001/jamaoto.2019.1728CrossRefPubMed

111.

Zou LQ, Linden L, Cuevas M, Metasch ML, Welge-Lüssen A, Hähner A, Hummel T (2019) Self-reported mini olfactory questionnaire (Self-MOQ): a simple and useful measurement for the screening of olfactory dysfunction. Laryngoscope. https://doi.org/10.1002/lary.28419CrossRefPubMed

112.

Doty RL, Shaman P, Dann M (1984) Development of the university of Pennsylvania smell identification test: a standardized microencapsulated test of olfactory function. Physiol Behav 32:489–502PubMed

113.

Dietz A, Haxel B, Müller A, Welkoborsky HJ, Drumm S, Guntinas-Lichius O, Chaberny I, Wienke A, Deitmer T, Heinrich D (2020) Handlungsempfehlungen DGHNO-KHC und BVHNO für die HNO-Elektiv-/nicht notfallmäßige Behandlung zu Corona-Zeiten (29.04.2020). Laryngorhinootologie 99(06):365–369PubMedPubMedCentral

114.

Vaira LA, Salzano G, Petrocelli M, Deiana G, Salzano FA, De Riu G (2020) Validation of a self-administered olfactory and gustatory test for the remotely evaluation of COVID-19 patients in home quarantine. Head Neck. https://doi.org/10.1002/hed.26228CrossRefPubMedPubMedCentral

115.

Petrocelli M, Ruggiero F, Baietti AM et al (2020) Remote psychophysical evaluation of olfactory and gustatory functions in early-stage coronavirus disease 2019 patients: the Bologna experience of 300 cases. J Laryngol Otol. https://doi.org/10.1017/S0022215120001358CrossRefPubMedPubMedCentral

116.

Lee DY, Lee WH, Wee JH, Kim JW (2014) Prognosis of postviral olfactory loss: follow-up study for longer than one year. Am J Rhinol Allergy 28(5):419–422. https://doi.org/10.2500/ajra.2014.28.4102CrossRefPubMed

117.

Reden J, Mueller A, Mueller C, Konstantinidis I, Frasnelli J, Landis BN, Hummel T (2006) Recovery of olfactory function following closed head injury or infections of the upper respiratory tract. Arch Otolaryngol Head Neck Surg 132:265–269PubMed

118.

Hüttenbrink KB et al Riech- und Schmeckstörungen. S2k-Leitlinie der DGHNOKHC. Stand: 31.10.2016. AWMF online. https://www.awmf.org/leitlinien/detail/ll/017-050.html. Zugegriffen: 30. Juni 2020

119.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus infected pneumonia in Wuhan, China. JAMA 323(11):1061–1069PubMedPubMedCentral

120.

Guan W, Zyi N, Hu Y, Liang W, Ou C, He J, Liu L, Shan H, Lei C, Hui DSC, Du B, Li L, Zeng G, Yuen K‑Y, Chen R, Tang C, Wang T, Chen P, Xiang J, Li S, Wang L, Liang Z, Peng Y, Wei L, Liu Y, Hu Y, Peng P, Wang J, Liu J, Chen Z, Li G, Zheng Z, Qiu S, Luo L, Ye C, Zhu S, Zhong N (2020) Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 382:1708–1720PubMed

121.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu Y, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506PubMedPubMedCentral

122.

Zhou F, Yu T, Du R, Fan G, Liu Y, Xiang J, Wang Y, Song B, Gu X, Guan L, Wie Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1055–1062

123.

Jin M, Tong Q (2020) Rhabdomyolysis as potential late complication associated with COVID-19. Emerg Infect Dis. https://doi.org/10.3201/eid2607.200445CrossRefPubMedPubMedCentral

124.

Beydon M, Chevalier K, Al Tabaa O, Hamroun S, Delettre A‑S, Thomas M, Herrou J, Riviere E, Mariette X (2020) Myositis as a manifestation of SARS-CoV‑2. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217573CrossRefPubMed

125.

Schoser et al (2020) SARS-CoV-2/COVID-19 und neuromuskuläre Erkrankungen. DGNeurologie 18:1–10. https://doi.org/10.1007/s42451-020-00198-2CrossRef

126.

Resivo DA, Centonze D, Alesina A, Marchese-Ragona R (2020) Myasthenia Gravis associated with SARS-coV‑2 infection. Ann Intern Med. https://doi.org/10.7326/L20-0845CrossRef

127.

Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P, Viganò M, Giovannelli G, Pirro F, Montisano DA, Appollonio I, Ferrarese C (2020) Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/NXI.0000000000000741CrossRefPubMedPubMedCentral

128.

Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, Franciotta D, Baldanti F, Daturi R, Postorino P, Cavallini A, Micieli G (2020) Guillain-Barré syndrome associated with SARS-coV‑2. N Engl J Med. https://doi.org/10.1056/NEJMc2009191CrossRefPubMedPubMedCentral

129.

Dinkin M, Gao V, Kahan J, Bobker S, Simonetto M, Wechsler P, Harpe J, Greer C, Mints G, Salama G, Tsiouris AJ, Leifer D (2020) COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology. https://doi.org/10.1212/WNL.0000000000009700CrossRefPubMedPubMedCentral

130.

Saccheri C, Morawiec E, Delemazure J, Mayaux J, Dubé B, Similowski T, Demoule A, Dres M (2020) ICU-acquired weakness, diaphragm dysfunction and long-term outcomes of critically ill patients. Ann Intensive Care 10(1):1PubMedPubMedCentral

131.

van Gassel RJJ, Baggerman MR, van de Poll MCG (2020) Metabolic aspects of muscle wasting during critical illness. Curr Opin Clin Nutr Metab Care 23(2):96–101PubMedPubMedCentral

132.

van Aerde N, Meersseman P, Debaveye Y, Wilmer A, Gunst J, Casaer MP, Bruyninckx F, Wouters PJ, Gosselink R, van den Berghe G, Hermans G (2020) Five-year impact of ICU-acquired neuromuscular complications: a prospective, observational study. Intensive Care Med. https://doi.org/10.1007/s00134-020-05927-5CrossRefPubMedPubMedCentral

133.

Pati S, Goodfellow JA, Iyadurai S, Hilton-Jones D (2008) Approach to critical illness polyneuropathy and myopathy. Postgrad Med J 84(993):354–360PubMed

134.

van der Schaaf M, Beelen A, de Vos R (2004) Functional outcome in patients with critical illness polyneuropathy. Disabil Rehabil 26(20):1189–1197PubMed

135.

AANEM (2020) COVID. https://www.aanem.org/Practice/COVID-19-Guidance. Zugegriffen: 10. Juni 2020

136.

Special-Collection-COVID-19. https://onlinelibrary.wiley.com/doi/toc/10.1002/(ISSN)1097-4598. Zugegriffen: 10. Juni 2020

137.

International MG/COVID-19 Working Group, Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF Jr, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak R (2020) Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci 15:412

138.

Solé G, Salort-Campana E, Pereon Y, Stojkovic T, Wahbi K, Cintas P, Adams D, Laforet P, Tiffreau V, Desguerre I, Pisella LI, Molon A, Attarian S (2020) FILNEMUS COVID-19 study group. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French RERare Health Care for Neuromuscular Diseases Network. Rev Neurol. https://doi.org/10.1016/j.neurol.2020.04.004CrossRefPubMed

139.

https://www.dgn.org/rubrik-dgn/stellungnahmen-der-dgn/3982-covid-19-und-menschen-mit-neuromuskulaeren-erkrankungen-empfehlungen-der-world-muscle-society. Zugegriffen: 10.06.20.

140.

Kluge S, Janssens U, Welte T, Weber-Carstens S, Marx G, Karagiannidis C (2020) Recommendations for critically ill patients with COVID-19. Med Klin Intensivmed Notfmed 115(3):175–177PubMed

141.

S3-Leitlinie Analgesie, Sedierung und Delir-Management in der Intensivmedizin (DAS-Leitlinie 2015); https://www.awmf.org/uploads/tx_szleitlinien/001-012l_S3_Analgesie_Sedierung_Delirmanagement_Intensivmedizin_2015-08_01.pdf, letzter Zugriff 30. Juni 2020

142.

Sutter R, Tisljar K, Marsch S (2018) Acute Neurologic complications during extracorporeal membrane oxygenation: a systematic review. Crit Care Med 46(9):1506–1513PubMed

143.

Yaghi S et al (2020) SARS2-coV‑2 and stroke in a New York Healthcare system. Stroke. https://doi.org/10.1161/STROKEAHA.120.030335CrossRefPubMedPubMedCentral

144.

Rajajee V, Riggs B, Seder DB (2017) Emergency neurological life support: airway, ventilation, and sedation. Neurocrit Care 27(Suppl 1):4–28PubMed

145.

Boone MD, Jinadasa SP, Mueller A, Shaefi S, Kasper EM, Hanafy KA et al (2017) The effect of positive end-expiratory pressure on Intracranial pressure and cerebral hemodynamics. Neurocrit Care 26(2):174–181PubMedPubMedCentral

146.

Chen H, Menon DK, Kavanagh BP (2019) Impact of altered airway pressure on Intracranial pressure, perfusion, and oxygenation: a narrative review. Crit Care Med 47(2):254–263PubMed

147.

Le Roux P, Menon DK, Citerio G, Vespa P, Bader MK, Brophy G et al (2014) The International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care: evidentiary tables: a statement for healthcare professionals from the Neurocritical Care Society and the European Society of Intensive Care Medicine. Neurocrit Care 21(Suppl 2):S297–S361PubMed

148.

Ohle R, McIsaac SM, Woo MY, Perry JJ (2015) Sonography of the optic nerve sheath diameter for detection of raised Intracranial pressure compared to computed tomography: a systematic review and meta-analysis. J Ultrasound Med 34(7):1285–1294PubMed

149.

Leslie-Mazwi TM, Fargen KM, Levitt M et al (2020) Preserving access: a review of stroke thrombectomy during the COVID-19 pandemic. AJNR Am J Neuroradiol 41:1136–1141. https://doi.org/10.3174/ajnr.A6606CrossRefPubMedPubMedCentral

150.

Lodigiani C, Iapichino G, Carenzo L et al (2020) Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. https://doi.org/10.1016/j.thromres.2020.04.024CrossRefPubMedPubMedCentral

151.

Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, de Aragón-Gómez F, Benito-Leónet J (2020) Miller fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. https://doi.org/10.1212/WNL.0000000000009619CrossRefPubMed

Titel: S1-Leitlinie: Neurologische Manifestationen bei COVID-19
Leitlinie der Deutschen Gesellschaft für Neurologie
verfasst von: Prof. Dr. med. Peter Berlit
Publikationsdatum: 12.10.2020
Verlag: Springer Medizin
Schlagwörter: Apoplex
Enzephalitis
Neurologische Beteiligung bei Infektionserkrankungen
Riechstörungen
COVID-19
SARS-CoV-2
Riechstörungen
Enzephalopathie
Erschienen in: DGNeurologie / Ausgabe 6/2020
Print ISSN: 2524-3446
Elektronische ISSN: 2524-3454
DOI: https://doi.org/10.1007/s42451-020-00254-x

Passend zum Thema

Leitlinien-Update und neue Pocket-Leitlinie vorgestellt von Prof. Möllmann

Vorhofflimmern

Die neue Leitlinie zur Behandlung von Herzklappenerkrankungen der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS) ist ab jetzt als deutschsprachige Pocket-Leitlinien abrufbar. Die wichtigsten Neuerungen des Updates finden Sie hier von Prof. Dr. Helge Möllmann aus Dortmund für Sie zusammengefasst.

Expertenrat: Wer profitiert vom Vorhofohr-Verschluss

Vorhofflimmern

Der interventionelle Verschluss des linken Vorhofohrs ist eine in den Leitlinien empfohlene Alternative zur oralen Antikoagulation bei Menschen mit Vorhofflimmern. Bei welchen Patientinnen und Patienten Sie konkret an diese Alternative denken sollten – dazu gibt Kardiologe PD Dr. Zisis Dimitriadis alltagstaugliche Tipps.

Abbott Structural Heart

Content Hub

Wir helfen Menschen mit Strukturellen Herzerkrankungen ihre Lebensqualität zu verbessern. Entdecken Sie unser einzigartiges Produktportfolio für ihre Patienten.

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Magazin

CME: Differenzialdiagnose von Kopf- und Gesichtsschmerzen

Starke Kopf- und Nackenschmerzen bei einer jungen Patientin

Deutsche Gesellschaft für Neurologie (DGN): Kongress 2020 im digitalen Format

Mitteilungen der Deutschen Gesellschaft für Neurologie

Facharztstandard und Leitlinien im Arzthaftungsrecht

Passend zum Thema

Leitlinien-Update und neue Pocket-Leitlinie vorgestellt von Prof. Möllmann

Expertenrat: Wer profitiert vom Vorhofohr-Verschluss

Abbott Structural Heart